


Our Pipeline

Innovative Projects in Development



ODD Orphan Drug Designation
 FT Fast Track
 QIDP Qualified Infectious Disease Product

* In combination with avelumab ** In combination with nivolumab



For updates



Debiopharm Group[™]

WE DEVELOP FOR PATIENTS

DEBIOPHARM INTERNATIONAL S.A.

CP 5911 - 1002 Lausanne, Switzerland

T +41 (0) 21 321 01 11 - info-international@debiopharm.com

www.debiopharm.com